Lamotrix (Lamotrigine)

Lamotrigine blocks voltage‑gated sodium channels on neuronal membranes, reducing rapid sodium influx during depolarisation. This stabilises the membrane, limits the release of excitatory neurotransmitters such as glutamate, and thereby diminishes neuronal hyper‑excitability that drives seizures and mood swings.

The dosage of lamotrigine is individualized. The prescribing clinician determines the starting dose and titration schedule based on the specific indication, patient age, renal function and any concomitant medicines. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Lamotrigine is classified as pregnancy category B1, indicating no evidence of fetal risk in animal studies and limited human data. It may be used during pregnancy when the therapeutic benefit outweighs potential risk, and plasma levels may need monitoring. Breastfeeding is generally considered compatible, but infant monitoring is advised.

To request Lamotrix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lamotrigine offers a broad spectrum covering both focal and generalized seizures and also provides mood‑stabilising benefits for bipolar disorder, which many older agents lack. Compared with carbamazepine or phenytoin, it typically has a more favourable cognitive side‑effect profile, though it requires careful titration to avoid skin reactions.

Lamotrix should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it if the packaging is damaged or the tablets appear discoloured.

Lamotrix is taken orally, usually with or without food, as a tablet swallowed whole with water. The exact dosing schedule, including frequency and any titration steps, is set by the prescribing clinician based on the patient’s condition and response.

The most serious risks include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, which require immediate medical attention. Rare but serious blood disorders (e.g., agranulocytosis) and hepatic dysfunction may also occur, so regular monitoring is recommended when risk factors are present.

Lamotrigine is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe hepatic or renal impairment, and dose adjustments are needed when used with interacting enzyme‑inducing antiepileptics. It should be avoided in patients who cannot be monitored for serious skin reactions.